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Abstract
Background: Major symptoms of chronic obstructive pulmonary disease (COPD) are chronic bronchitis and
emphysema leading from lung tissue destruction, that is an effect of an imbalance between metalloproteinases
(MMPs) and their tissue inhibitors activity. As potential factor involved in this COPD pathogenesis, MMP-12 is
considered. We investigated the role of genetic polymorphism and protein level of MMP-12 in the COPD
development among Poles.
Methods: We analyzed − 82 A > G SNP in the promoter region of MMP-12 gene (rs2276109) among 335 smoked
COPD patients and 309 healthy individuals, including 110 smokers. Additionally, 60 COPD patients and 61 controls
(23 smokers) were tested for serum levels of MMP-12 using ELISA. All subjects were analyzed for lung function
using spirometry (FEV1% and FEV1/FVC parameters).
Results: We observed that -82G allele and -82GG homozygous genotype frequencies of the SNP rs2276109 were
significantly lower in COPD patients than in controls (12.5% vs 16.9%, respectively; χ2 = 4.742, p = 0.02 for allele and
0.5% vs 3.9%, respectively; χ2 = 9.0331, p = 0.01 for genotype). Moreover, −82G allele was more frequent in controls
smokers than in non-smokers (22.3% vs 14.1%, χ2 = 6.7588, p = 0.01). Serum level of MMP-12 was significantly higher
in COPD patients than in controls groups (6.8 ng/ml vs 3.3 ng/ml, respectively; F = 7.433, p < 0.0001), although
independently of analyzed gene polymorphisms. Additionally, no correlation between parameters of lung function
(FEV1% and FEV1/FVC) and protein level was found.
Conclusions: We found that -82G allele of SNP rs2276109 was associated with reduced risk of COPD, and COPD
patients released more MMP-12 than healthy individuals, but independently on this SNP.
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Background
Chronic obstructive pulmonary disease (COPD) is a
multifactorial disease with gene-environment interaction
leading to airflow limitation through the respiratory tract
that is not fully reversible [1]. Initially, inflammation of
the respiratory tract can protect against the stimuli of
harmful gases and dusts, but eventually it results in a
chronic inflammatory state [2]. This phenomenon
additionally leads to pulmonary emphysema, which is
considered, together with chronic bronchitis, as a major
symptom of COPD [3]. The emphysema is associated
with lung tissue destruction and a loss of lung elasticity,
which seem to be the effects of an imbalance in the
action of proteases and antiproteases, including metallo-
proteinases (MMPs) [3]. Due to the capability of degrad-
ing matrix proteins (elastin, collagens) MMPs play a
crucial role in cell and tissue behaviors such as cell
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proliferation/migration, angiogenesis, apoptosis, tissues
repair and remodeling. This MMP activity is physiologic-
ally expected but needs to be controlled primarily by
tissue inhibitors of metalloproteinases (TIMPs) that are
able to bind to an active site of MMPs, inhibiting their
action [4]. However, in pathological conditions such as
COPD, chronic inflammation is stimulated by matrix
proteolysis-related facilitation of immune cell migration
to lung tissues [3].
With regard to above-mentioned MMP function and
under the hypothesis of COPD such as protease-antipro-
tease imbalance, a previous study implicated
metalloproteinase 12 (MMP-12) in the pathogenesis of
COPD [5]. MMP-12, also called macrophage metalloe-
lastase, is an enzyme released by macrophages that
breaks down elastin [6]. It seems to be necessary for
emphysema development [7, 8], and specifically, it was
shown that elevated levels of MMP-12 in the sputum are
associated with emphysema severity in COPD [9–11].
The suggested role of MMP-12 is consistent with the
importance of alveolar macrophages (AM) in the patho-
genesis of COPD [12]. Macrophages exhibit two distinct
phenotypes: M1 producing proinflammatory cytokines,
e.g. TNF, IL-6 and IL-12, and M2 with secretion of
anti-inflammatory molecules (TGF-β, IL-10) [13]. In
COPD it was shown that AM are characterized by both
M1 surface phenotypes and functional properties due to
the high amount of M1 cytokines, such as TNF and IL-8
[14]. Generally, COPD-related AM produce destructive
proteases and their number was ~ 10-fold higher in the
lungs of smokers than non-smokers (reviewed by Gharib
et al) [15].
Due of this, over-expression of MMP-12 seems to be a
result of an increased influx of macrophages, but on the
other hand, it was shown that a functional variant in the
MMP-12 promoter (a substitution A-to-G at position −
82; rs2276109) affects the enzyme expression level and
COPD susceptibility. It is showed that this substitution
influences the binding of the AP-1 (activator protein 1)
transcription factor, which possess higher affinity for the
-82A allele [16]. As a result, the promoter activity and
the MMP-12 expression level may be decrease by allele
G, which is associated with a beneficial effect on lung
function in children with asthma, as well as a reduced
risk for adult smokers to develop COPD [17].
Hence, the aim of this study was to investigate the role
of SNP rs2276109 in COPD development in Polish
patients and its impact on both a MMP-12 protein level
in serum and the lung function spirometry parameters.
Methods
Study populations
Three hundred and thirty-five patients (248 males and
87 females) with COPD were enrolled in the study.
COPD diagnosis was performed according to the GOLD
(Global Initiative for Chronic Obstructive Lung Disease)
standards and routinely included the lung function test
by spirometry performed twice: before and 15–20 min
after bronchodilator application (400 μg of salbutamol).
Only patients for whom the bronchial relaxation trial
was negative and the post-bronchodilator FEV1/FVC
ratio was reduced below the lower limit of the norm
(< 0.70) were included in the study. In accordance with
the GOLD grading system [1], the cases were classified as
patients with mild (11% of patients), moderate (49%) and
severe/very severe (40%) COPD. Exclusion criteria were
alpha-1-antitrypsin deficiency, coexistence of asthma and
COPD, history of bronchial asthma and no history of
smoking. All patients were recruited from the inpatient
and outpatient populations of the University Hospital in
Cracow, Specialized Hospital of Ministry of Internal
Affairs and Administration (MSWiA) in Głuchołazy and
the Department of Pulmonology, Opole Voivodeship
Hospital.
In the healthy control group 309 volunteers (80 men
and 229 women) were recruited. All subjects were not
diagnosed for COPD or any other lung disease and were
once spirometrically tested for lung function. Only
individuals who exhibited normal lung function were
subjected to the test (mean FEV1% of 91.7%). Among
controls, 110 individuals were defined as smokers (current
and former), and 199 participants were never smokers.
The groups were analyzed for single nucleotide poly-
morphisms, but 60 patients with COPD and 61 control
individuals (23 smokers and 38 never smokers) were
randomly selected for examination of protein level.
All members of the patients and control group were of
Polish Caucasians ethnicity, and detailed characteristics
are shown in Table 1.
The project was approved by the Ethics Committee of
Opole Voivodship. Signed informed consent was ob-
tained from all persons tested.
DNA isolation and SNP genotyping
gDNA was extracted from whole blood using the Gene-
MATRIX Quick Blood DNA Purification Kit (Eurx,
Germany) following the manufacturer’s instructions.
The -82A > G polymorphism of the MMP-12 gene
(rs2276109) was genotyped using a TaqMan Genotyping
Assay (Applied Biosystems, USA) on a 7500 Fast
Real-Time System instrument and SDS 2.0 software (Ap-
plied Biosystems) in accordance with the manufacturer’s
protocol. Briefly, 10 μl of PCR mixture contained 1x
concentrated genotyping master mix, 1x TaqMan Geno-
typing Assay probes and primer mix, and up to 6.5 ng of
DNA. The PCR program was performed under the
following conditions: 95 °C, 10 min; 40 cycles of 15 s at
95 °C, 60 s at 60 °C. Allelic discrimination was based on
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measuring the fluorescence signals generated by two
MGB TaqMan probes, one for each allele.
Analysis of protein level
The serum level of MMP-12 was measured using
enzyme-linked immunosorbent assay (ELISA; EIAab,
China) accordingly to the manufacturer’s instructions
using non-diluted serum samples. The absorbance was
read with the Epoch microplate reader (BioTech, Wi-
nooski, VT, USA) at the wavelength of 450 nm. Concen-
trations of proteins in samples were calculated with the
equation of the standard curve using Gen5 software
(BioTech, Winooski, VT, USA).
Statistical analysis
Testing of the Hardy–Weinberg equilibrium for the ana-
lyzed SNP was performed using the χ2 test and EpiInfo
software. Case-control differences in alleles and geno-
types were estimated using the two-tailed Fisher’s exact
test and χ2 test with Yates’ correction, respectively and
GraphPad InStat 3 software. Moreover, logistic regression
with binary response (a disease status) for the multiple
inheritance models (co-dominant, dominant, recessive,
over-dominant and log-additive) was used (www.snpstats.
net). In spirometry data and protein level analyses, the
Shapiro-Wilk method was used for testing normality
of samples. Relevant statistical comparisons were per-
formed using one-way analysis of variance (ANOVA),
and appropriate Tukey post-hoc tests were applied
when significant interactions in ANOVA were identified.
These statistical analyses were performed with Statistica
v.12 (StatSoft, Inc., OK, USA). P-values ≤0.05 were consid-
ered significant.
Results
Three hundred and thirty-four patients affected with
COPD and three hundred and four healthy individuals
were typed for SNP rs2276109 in the gene encoding
MMP-12. The observed genotype frequencies were very
close to the values expected for both case and control
populations according to the Hardy-Weinberg equilib-
rium (p > 0.05, data not shown).
When allele and genotype frequencies of poly-
morphism of A-to-G at position − 82 were compared,
a significant difference was found. The -82G allele
was significantly less frequent in the COPD patients
than both in the controls (12.5% vs 16.9%, respect-
ively, p = 0.02; OR = 0.70) and in the control smoker
group (12.5% vs 22.3%, p = 0.0005, OR = 0.50, Fig. 1).
In addition, homozygotes for the G allele (GG geno-
type) were rarer in the COPD group than in the con-
trols (0.5% vs 3.9%, respectively, p = 0.01 and OR =
0.14; Fig. 1 and Additional file 1) as well as in control
groups divided into two groups accordingly to the
smoking status (4.5%, p = 0.0005 and 3.5%, p = 0.03
for smokers and non-smokers, respectively). Addition-
ally, the difference between patients with COPD was
observed in recessive (AA+AG vs. GG) model of in-
heritance (see Additional file 1). Moreover, smoker
controls significantly differ from non-smokers in -82G
allele distribution (22.3% vs 14.1%, p = 0.01). On the
other hand, no statistically significant differences in
-82A > G allele and genotype frequencies between
COPD patients’ groups divided accordingly to the
disease severity were found (data not shown).
The serum MMP-12 levels of 60 patients with
COPD and 61 age-matched controls were measured
by ELISA. As shown in Fig. 2, patients with COPD
had significantly higher serum MMP-12 protein levels
than controls (6.8 ± 3.3 ng/ml and 3.4 ± 1.3 ng/ml,
respectively, p < 0.0001). Controls were divided into
smoker and non-smoker groups, but similar MMP-12
protein levels were found in both groups (3.2 ± 1.1
and 3.5 ± 1.5 ng/ml, respectively; p = 0.45), with signifi-
cantly lower values compared to patients with COPD
(p < 0.0001 for both subgroups).
Table 1 Characteristics of the analyzed groups
Groups (N) Age Sex FEV1 FEV1/FVC Smokers
(years) (women/men) (% predicted) (% predicted) (%)
COPD (335) 67.9 ± 9.2 248/87b 55.5 ± 18.5b 52.2 ± 16.0b 100b
CTR (309) 68.0 ± 6.6 80/229 91.7 ± 22.8 89.2 ± 25.8 35.5
CTR smokers (110) 68.4 ± 5.2 73/37 93.3 ± 22.0 91.1 ± 19.5 100
CTR non-smokers (199) 65.8 ± 9.6 157/42 91.0 ± 23.6 88.1 ± 28.7 0
COPDa (60) 70.4 ± 9.0 13/47b 46.6 ± 18.5b 58.1 ± 16.4b 100b
CTRa (61) 67.8 ± 6.7 46/15 90.4 ± 22.5 92.6 ± 23.2 37.7
CTR smokersa (23) 67.7 ± 5.6 15/8 93.2 ± 21.9 88.2 ± 16.4 100
CTR non-smokersa (38) 67.9 ± 7.6 31/7 90.6 ± 22.0 90.7 ± 18.0 0
N numbers of individuals, COPD chronic obstructive pulmonary disease groups, CTR control group; a, groups for protein levels analyses, FEV1 forced expiratory
volume in 1 s, FEV1/FVC Tiffeneau-Pinelli index – ratio of forced expiratory volume in 1 s and forced vital capacity;
b, difference to the control group statistically
significant at the level of p < 0.00001
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For the MMP-12 -82A >G variants, there were no
statistically significant differences in the level of MMP-12
protein among the different genotypes carriers, independ-
ently in COPD and control groups (Fig. 3). Moreover,
relationships between MMP-12 polymorphism and lung
function parameters among both patients with COPD and
controls were analyzed. As shown in Table 2, there were
no significant relationships between allele/genotypes dis-
tribution of − 82 A >G variants and FEV1 and FEV1/FVC
(mean of % predicted).
Discussion
In this study, we found that rs2276109 (a substitution
A-to-G at position − 82) polymorphism in the MMP-12
gene can influence susceptibility to COPD in the Polish
population, and we confirmed that allele G carriers seem
to be protected against the disease. The present study
revealed a significant difference in MMP-12 levels
between COPD patients and controls. Additionally, no
significant relationships were observed between lung
function parameters or MMP-12 protein level and the
Fig. 1 Alleles (a) and genotypes (b) distribution of − 82 A-to-G SNP of MMP-12 gene (rs2276109) in COPD patients and healthy control groups.
Legend: COPD, patients with chronic obstructive pulmonary disease; CTR – controls; OR (95%CI) calculated for -82G allele in COPD patients-
controls comparison was of 0.70 (0.51–0.95)
Fig. 2 MMP-12 protein level in serum of COPD patients and healthy control groups. Legend: COPD, patients with chronic obstructive pulmonary
disease; CTR – controls; data expressed as medians (25 and 75% percentiles)
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MMP-12 -82A > G polymorphism. To the best of our
knowledge, this is the first study to analyze the rela-
tionship between rs2276109 and MMP-12 protein
level in COPD.
COPD comprises disorders such as chronic bronchitis
and emphysema which develop because of air pollution-
related low-grade inflammation and destruction of lung
tissue, especially extracellular matrix (ECM) [15]. It
seems that MMP-12 plays a crucial role in this
phenomenon: in a murine model it was shown that
the enzyme breaks down the ECM component elastin,
and MMP-12-null mice exposed to cigarette smoke
avoided emphysema development [7]. In humans,
however, as Gharib et al. reviewed, it is very likely
that MMP-12 is not effective in direct elastin degrad-
ation but could have an impact on this mechanism by
affecting macrophage behavior [15].
Macrophages are a cell type possessing dual na-
ture: (i) a major population which patrols lower
airspaces in normal conditions, and (ii) predominant
inflammatory cells that are recruited in response to
cigarette smoke [18]. Due to this, it cannot be ex-
cluded that the COPD-related increased level of
MMP-12 that was observed in our study is an effect
such as stimulated macrophage recruitment in situ.
All our patients with COPD were classified as
smokers, and it has been previously reported that
expression of MMP-12 increased in smokers [10],
but this phenomenon was not confirmed in our
control smoker and non-smoker subgroups. It could
be associated with the finding of greater expression
as well as activity of MMP-12 in the sputum of
patients with COPD than in smokers without airflow
limitation [19].
Fig. 3 MMP-12 gene polymorphism −82 A-to-G SNP impact on MMP-12 protein level in serum of COPD patients and healthy control groups (A,
allele impact on MMP-12 protein level; B, genotype impact on MMP-12 protein level). Legend: COPD, patients with chronic obstructive pulmonary
disease; CTR – controls; data expressed as medians (25 and 75% percentiles); no significant difference in mean MMP-12 protein levels between
carriers with different − 82 A > G alleles/genotypes in one-way ANOVA test, Tuckey post-hoc test were not conducted
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A allele 333 55.5 ± 18.6 52.3 ± 16.0 297 92.0 ± 23.4 86.2 ± 23.2 105 92.8 ± 21.8 92.0 ± 19.5 192 91.5 ± 23.3 85.8 ± 24.5
G allele 82 54.1 ± 15.8 51.4 ± 17.9 93 92.1 ± 20.7 92.8 ± 24.7 14 94.9 ± 21.9 90.7 ± 20.6 49 88.5 ± 20.4 95.8 ± 27.8
AA 253 55.9 ± 19.3 52.5 ± 15.4 216 92.0 ± 23.4 86.2 ± 23.2 66 92.0 ± 22.2 92.8 ± 18.5 150 91.8 ± 24.2 85.3 ± 26.5
AG 80 53.9 ± 18.0 51.7 ± 18.1 81 92.6 ± 20.1 91.9 ± 21.7 39 94.0 ± 21.4 91.5 ± 21.2 42 90.0 ± 19.9 93.4 ± 22.3
GG 2 56.7 ± 17.4 44.9 ± 18.5 12 88.5 ± 25.3 99.2 ± 40.2 5 101.0 ± 22.6 84.3 ± 15.9 7 79.7 ± 22.3 109.9 ± 47.8
P value* 0.71 0.90 0.95 0.10 0.75 0.26 0.30 0.77
N number of individuals/alleles/genotypes, COPD chronic obstructive pulmonary disease groups, CTR control group, FEV1 forced expiratory volume in 1 s, FEV1/FVC
Tiffeneau-Pinelli index – ratio of forced expiratory volume in 1 s and forced vital capacity; *, no significant difference in mean of lung function parameters
between carriers with different −82 A > G alleles/genotypes in one-way ANOVA test, Tuckey post-hoc test were not conducted
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On the other hand, the enzyme level seems to be re-
lated to promoter polymorphism rs2276109. We re-
vealed that a minor allele of SNP rs2276109 seems to
protect against COPD development (variant protective
effect corresponds with OR value less than 1; Fig. 1).
This phenomenon could be explained by functional
significance of the -82G allele for decreased activity of
the MMP-12 gene promoter, which is suggested by less
efficient binding of transcription factor AP-1 to the G
allele [16, 17]. The AP-1 binding region together with
STAT-5 is probably critical for induction of MMP-12
expression [20]. Nevertheless, we did not observe a rela-
tionship between rs2276109 and MMP-12 protein level,
similarly to finding in obesity patients [21]. Therefore, it
is most likely that, besides promoter polymorphism,
MMPs levels depend on the transcriptional control in-
cludes epigenetic mechanisms such as DNA methylation
and histone acetylation, and post-transcriptional regula-
tion is by cytosolic mRNA stability [22]. Final MMP-12
concentration in blood seems to be a results of this
rigorous control system as well as e.g. number of the
cells which secrete the enzyme. On the other hand, in
this study, no significant correlation was found between
this variant and lung function parameters of COPD,
similarly to previous studies [5, 23, 24]. This result
(Table 2), however, contrasts with a finding that this
variant (−82G) was associated with increased FEV1 and
delayed onset of the disease together with the above-
mentioned reduced risk of COPD [17].
Several limitations of the present study should be
taken into account. We measured MMP-12 only at the
protein level without mRNA expression level analysis.
Second, the protein level was measured in blood, but
not in situ using either sputum or bronchoalveolar
lavage, which should better reflect the MMP-12 as well
as macrophage phenomenon occurring in the COPD-re-
lated lung microenvironment. Unfortunately, data about
numbers of macrophages and other immunocompetent
cells (e.g. neutrophils) were also unavailable in our study.
The mentioned limitations were related to the samples
gathering and missing data seem to be important for
consideration in further research.
Conclusion
We confirm that patients with COPD exhibited more
MMP-12 protein, and the -82G allele of SNP rs2276109
was more frequent in controls than in COPD patients
group. On the other hand, no relationship between the
mentioned genetic polymorphism and MMP-12 level
was found. Nevertheless, our data, together with other
findings, suggest that MMP-12 affects COPD develop-
ment. In our opinion, the molecule could be deliberated
in further research as a useful molecular marker as well
as therapy target in COPD management.
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Additional file 1: Table 1S. Logistic regression analysis of association
between -82 A-to-G SNP of MMP12 gene (rs2276109) and COPD – the
multiple inheritance models. Description of data: This table contains the
logistic regression results of modeled association between SNP rs2276109
of MMP12 gene and COPD. (DOCX 16 kb)
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